HOOKIPA Pharma Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases using its proprietary viral vector technology. The company's lead product candidates, including HB-201 and HB-202, target HPV-related cancers and are currently in clinical trials, primarily in the United States and Europe.
HOOKIPA Pharma generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies for the development of its immunotherapy products. The high gross margin of 93% indicates strong pricing power once products reach commercialization, although the current lack of revenue reflects its early-stage development status.
Clinical trial results for HB-201 and HB-202, particularly Phase 2 data expected in 2026
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA or EMA
Market sentiment regarding the biotechnology sector
Regulatory changes affecting drug approval processes
Technological disruption in immunotherapy approaches
Emergence of alternative therapies for HPV-related cancers
Increased competition from larger biotech firms with more resources
High cash burn rate leading to potential liquidity issues if funding is not secured
Dependence on external funding for R&D activities
low - As a biotechnology firm, HOOKIPA's performance is less tied to economic cycles and more dependent on clinical success and regulatory approvals.
Interest rates can affect HOOKIPA's financing costs for R&D, but given its low debt levels, the impact is minimal. Higher rates could also dampen investor sentiment towards high-risk biotech stocks.
minimal - The company has very low debt levels (Debt/Equity of 0.02), reducing sensitivity to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant price fluctuations, evidenced by a 27.8% return over six months and an 8.5% return over three months.